Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2026)
Vir Biotechnology (VIR) posted Return on Capital Employed of 50.19% for Q1 2026, up 3.85% sequentially from 52.2% in Q4 2025, and up 299.0% YoY from 12.58% in Q1 2025.
Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2026) Analysis & Trends
Vir Biotechnology has reported Return on Capital Employed for 8 years, with the latest figure at 50.19% in Q1 2026.
- Quarterly Return on Capital Employed rose 299.0% year-over-year to 50.19% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 50.19% (up 299.0% YoY) and the FY2025 annual result came in at 43.26%, down 511.0% from the prior year.
- Return on Capital Employed rose to 50.19% in Q1 2026 per VIR's latest filing, from 52.2% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 92.72% in Q1 2022 and troughed at 53.22% in Q3 2025.
- A 5-year average of 15.6% and a median of 35.24% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 15032 bps in 2022, then slumped 10713 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 37.22% in 2022, then slumped by 202 bps to 37.88% in 2023, then fell by 17 bps to 44.18% in 2024, then decreased by 18 bps to 52.2% in 2025, then increased by 4 bps to 50.19% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 50.19%, 52.2%, and 53.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | -27.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.33% |
| Mar 31, 2026 | -50.19% |
| Dec 31, 2025 | -52.20% |
| Sep 30, 2025 | -53.22% |
| Jun 30, 2025 | -52.96% |
| Mar 31, 2025 | -53.18% |
| Dec 31, 2024 | -44.18% |
| Sep 30, 2024 | -41.52% |
| Jun 30, 2024 | -34.52% |
| Mar 31, 2024 | -35.24% |
| Dec 31, 2023 | -37.88% |
| Sep 30, 2023 | -35.15% |
| Jun 30, 2023 | -14.09% |
| Mar 31, 2023 | -14.41% |
| Dec 31, 2022 | 37.22% |
| Sep 30, 2022 | 66.20% |
| Jun 30, 2022 | 57.44% |
| Mar 31, 2022 | 92.72% |
| Dec 31, 2021 | 33.90% |
| Sep 30, 2021 | -28.82% |